Influence of Four Radiotracers in PET/CT on Diagnostic Accuracy for Prostate Cancer: A Bivariate Random-Effects Meta-Analysis

Liu, Junzhong; Chen, Zhongfeng; Wang, Tianyu; Liu, Li; Zhao, Lei; Guo, Guangtao; Wang, Dongqing

doi:10.1159/000445639

Cited by 19 publications

(28 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, in 18 F-FDG PET/CT studies, the tracer showed overlapping uptake in normal, benign and malignant tissues resulting in poor specificity (18-20). A recent systematic review and meta-analysis of 3,586 men with PCa compared the diagnostic accuracy among four PET/CT radiotracers ( 18 F-FDG, 11 C-choline, 18 F-choline and 11 C-acetate) suggesting diagnostic superiority of 18 F-choline, ranked as the most favorable with the highest value of AUC (AUC =0.94; 95% CI: 0.92–0.96), whereas 18 F-FDG was the least favorable (AUC =0.73; 95% CI: 0.69–0.77) for PCa detection (2). On the other hand, a recent review suggests that, 18 F-FDG might be helpful for restaging purposes in patients with advanced PCa metastatic disease.…”

Section: F-fluorodeoxyglucose (18f-fdg)mentioning

confidence: 98%

See 1 more Smart Citation

Positron emission tomography (PET) in primary prostate cancer staging and risk assessment

Bednarova

Lindenberg

Vinsensia

et al. 2017

Transl. Androl. Urol.

View full text Add to dashboard Cite

Prostate cancer (PCa) is one of the few neoplasms that are not well served by 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET). As a result, a number of PET tracers have been developed to target particular biological features of PCa. Such agents can be used for diagnosis, staging, identification of biochemical recurrence (BCR) and evaluation of metastatic disease. Here, we focus on primary disease and local staging. To date, magnetic resonance imaging (MRI) has proven superior to PET in the imaging of primary PCa. However, some PET agents have shown remarkable promise in staging high-risk PCa (defined as any combination of a clinical T3, a PSA score >20 ng/mL, or a Gleason score of 8–10), as well as biochemical relapse after definitive therapy and metastatic PCa. PET agents can be divided into those that interrogate tumor metabolism (18F-FDG, 11C-Choline, 18F-Choline, 11C-Acetate, 18F-FACBC), hormone receptors (18F-FDHT), and other targets such as prostate specific membrane antigen (PSMA) (68Ga-PSMA, 18F-DCFBC, 18F-DCFPyl) or gastric releasing peptide (18F-GRP or 18F-Bombesin). In this review, we compare the available PCa targeted PET tracers utilized in staging of high risk tumors.

show abstract

Section: F-fluorodeoxyglucose (18f-fdg)mentioning

confidence: 98%

“…For patients with organ-confined PCa that is considered intermediate or high risk, primary curative approaches, including radical prostatectomy (RP) or radiation therapy (RT), are advised provided that there is no evidence of metastatic disease. On the other hand, when the disease is metastatic, systemic therapies are more suitable (2). …”

Section: Introductionmentioning

confidence: 99%

Positron emission tomography (PET) in primary prostate cancer staging and risk assessment

Bednarova

Lindenberg

Vinsensia

et al. 2017

Transl. Androl. Urol.

View full text Add to dashboard Cite

show abstract

“…Radiation exposure 29 Cirrhosis and steatosis (induced by chemotherapy); imaging of cirrhotic or steatotic liver can be improved by using contrast agent 27,28 . Lack of anatomical orientation 23 Sensitivity, specificity of system Increases with field strength 19,25,55 Specificity > 90%, but sensitivity only 60% 20…”

Section: Iterativementioning

confidence: 99%

“…Lack of sensitivity owing to very low light levels 33 . Specificity dependent on tracer used 55 Increase in imaging distance degrades sensitivity and spatial resolution 34,37 . Sensitivity and specificity dependent on system and tracer 55 FOV, field of view; SLN, sentinel lymph node; SPECT, single-photon emission CT.…”

Section: Raman Spectroscopymentioning

confidence: 99%

Modalities for image- and molecular-guided cancer surgery

Stammes

Bugby

Porta

et al. 2018

British Journal of Surgery

View full text Add to dashboard Cite

Background: Surgery is the cornerstone of treatment for many solid tumours. A wide variety of imaging modalities are available before surgery for staging, although surgeons still rely primarily on visual and haptic cues in the operating environment. Image and molecular guidance might improve the adequacy of resection through enhanced tumour definition and detection of aberrant deposits. Intraoperative modalities available for image-and molecular-guided cancer surgery are reviewed here.Methods: Intraoperative cancer detection techniques were identified through a systematic literature search, with selection of peer-reviewed publications from January 2012 to January 2017. Modalities were reviewed, described and compared according to 25 predefined characteristics. To summarize the data in a comparable way, a three-point rating scale was applied to quantitative characteristics. Results:The search identified ten image-and molecular-guided surgery techniques, which can be divided into four groups: conventional, optical, nuclear and endogenous reflectance modalities. Conventional techniques are the most well known imaging modalities, but unfortunately have the drawback of a defined resolution and long acquisition time. Optical imaging is a real-time modality; however, the penetration depth is limited. Nuclear modalities have excellent penetration depth, but their intraoperative use is limited by the use of radioactivity. Endogenous reflectance modalities provide high resolution, although with a narrow field of view. Conclusion:Each modality has its strengths and weaknesses; no single technique will be suitable for all surgical procedures. Strict selection of modalities per cancer type and surgical requirements is required as well as combining techniques to find the optimal balance.

show abstract

“…18 F] fluoro-D-glucose, or 18 F-FDG; however, these tracers are limited by sensitivity, specificity, metabolism and excretion methods [17][18][19]. Thus, the purpose of this review is to highlight the advantages and limitations of current novel PET tracers in the detection of biochemical recurrent and metastatic PCa.…”

mentioning

confidence: 99%

PET Imaging of Recurrent and Metastatic Prostate Cancer with Novel Tracers

et al. 2016

View full text Add to dashboard Cite

Early detection of recurrent prostate cancer (PCa) is of paramount importance to deliver prompt and accurate therapy reducing the chance of progression to metastatic disease. However, current imaging modalities such as conventional computed tomography, MRI and PET scanning do not provide sufficient sensitivity, especially at lower prostate-specific antigen values. Moreover, biological characterization of PCa has become increasingly important to provide patient-specific therapy and current imaging poorly characterizes disease aggressiveness. The current uprise of novel PET tracers in recurrent and metastatic PCa shows promising, yet variable sensitivities and specificities in detection, indicating the need for further studies. In this review, we highlight current and new PET tracers that have been developed to improve the detection of recurrent and metastatic PCa. KEYWORDS• biochemical recurrenceProstate cancer (PCa) is the most common noncutaneous malignancy in American men with 180,890 new cases and 26,120 deaths estimated in 2016 alone [1]. Recent advances in detection, monitoring and treatment of the disease include the growing use of multiparametric MRI, transrectal ultrasound/fusion MRI-guided biopsies and new focal therapies. Primary definitive therapy options for PCa remain radiation therapy (RT) and radical prostatectomy (RP), which are used with curative intent, although both methods have improved over time. Despite the high success rates in primary treatment, 15-25% of patients still experience biochemical recurrence (BCR), following primary definitive therapy with RP or RT [2][3][4][5][6][7]. The definition of BCR varies between therapy methods. For instance, following RP a rising PSA above 0.2 ng/ml defines BCR whereas following RT BCR is defined as a PSA change of 2.0 ng/ml above the nadir following RT and is known as the Phoenix criteria [7]. As rising PSA in post primary therapy patients is an indicator of PCa BCR, close monitoring of serum PSA levels following treatment is critical [7,8]. In the case of BCR, early detection and initiation of therapy is a key to better long-term outcomes. Early intervention is associated with a lower rate of metastatic disease. Thus, accurate and early detection of recurrence leading to earlier treatment will aid in hindering the progression of BCR to metastatic disease.Multiple imaging modalities exist for the detection of recurrent PCa including computed tomography (CT), bone scintigraphy, MRI and PET. However, the need for more sensitive and specific imaging modalities to detect early recurrent and metastatic PCa has been prompted by evidence supporting early treatment. In addition to more sensitive and specific imaging, there has been a 'thrust' toward personalized and targeted management to discover disease phenotype and predict clinical outcomes earlier, which PET/CT has answered the call [9]. The future demands more For reprint orders, please contact: reprints@futuremedicine.com

show abstract

Influence of Four Radiotracers in PET/CT on Diagnostic Accuracy for Prostate Cancer: A Bivariate Random-Effects Meta-Analysis

Cited by 19 publications

References 81 publications

Positron emission tomography (PET) in primary prostate cancer staging and risk assessment

Positron emission tomography (PET) in primary prostate cancer staging and risk assessment

Modalities for image- and molecular-guided cancer surgery

PET Imaging of Recurrent and Metastatic Prostate Cancer with Novel Tracers

Contact Info

Product

Resources

About